Yunpeng Bai

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Allogeneic Hematopoietic Stem Cell Transplantation

Photodynamic Therapy

Top Venues

Molecular cancer research : MCR

Chemical science

Cancer research communications

Molecules (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Frederick Nguele Meke, Yunpeng Bai, Diego Ruiz-Avila, Colin Carlock, Jinan Ayub, Jinmin Miao, Yanyang Hu, Qinglin Li, Zhong-Yin Zhang
Inhibition of PRL2 upregulates PTEN and attenuates tumor growth in Tp53-deficient sarcoma and lymphoma mouse models. Cancer research communications (2023)
Jinmin Miao, Jiajun Dong, Yiming Miao, Yunpeng Bai, Zihan Qu, Brenson A Jassim, Bo Huang, Quyen D Nguyen, Yuan Ma, Allison A Murray, Jinyue Li, Philip S Low, Zhong-Yin Zhang
Discovery of a selective TC-PTP degrader for cancer immunotherapy. Chemical science 14 (44) (2023)
Hongxia Chen, Yunpeng Bai, Michihiro Kobayashi, Shiyu Xiao, Sergio Barajas, Wenjie Cai, Sisi Chen, Jinmin Miao, Frederick Nguele Meke, Chonghua Yao, Yuxia Yang, Katherine Strube, Odelia Satchivi, Jianmin Sun, Lars Rönnstrand, James M Croop, H Scott Boswell, Yuzhi Jia, Huiping Liu, Loretta S Li, Jessica K Altman, Elizabeth A Eklund, Madina Sukhanova, Peng Ji, Wei Tong, Hamid Band, Danny T Huang, Leonidas C Platanias, Zhong-Yin Zhang, Yan Liu
PRL2 phosphatase promotes oncogenic KIT signaling in leukemia cells through modulating CBL phosphorylation. Molecular cancer research : MCR (2023)
Jinmin Miao, Yunpeng Bai, Yiming Miao, Zihan Qu, Jiajun Dong, Ruo-Yu Zhang, Devesh Aggarwal, Brenson A Jassim, Quyen Nguyen, Zhong-Yin Zhang
Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity. Molecules (Basel, Switzerland) 28 (19) (2023)